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The best hid phns of mice and mn gmong ofr astray 
-Roher~ W. Bums 
When the great 19th century Scotrish poet Robert Burns 
wrote perhaps his most memorable line, he was undoubtedly 
commenting on human nature, nc; medical practice. Nane- 
theless, the cuurse of medical science, like all human en- 
deavors, ha5 demonstrated that propused solutions atlen 
lead to unexpected new problems. The case of angioplaaty 
and restenosis (1) provides perhaps Ihe latest example tolhis 
well worn paradigm. Although the initial success rate of 
coronary angioplasty for opening obstructed coronary arter- 
ies approaches 95%, restenosis ucculs at the site of an& 
plasty in 25% to 50% of patients within 6 months, regardless 
of the type of angioplasty procedure used (2-6). 
Recoil of rhe vessel wall and thrombus formation at the 
site of iqjury undoubtedly contribute to reslenosis (7.8). 
However, the primary pathophysiologic mechanism in- 
volves whar seems to be an exaggerated healing response of 
medial smooth muscle cells to vascular injury. The itiury 
induces smooth muscle cells to proliferate and to migrate to 
the subintima. where the smooth muscle cells continue to 
proliieratc and secrete extracellular malrix (9-13). These 
processes cause the neointimal mass to expand and gradu- 
ally encroach on the coronary lumen. Ultimately, the ex- 
panding lesion increases resistance to blood flow and causes 
ischemic symptoms. 
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Given this pathophysiologic mechanism. the problem of 
controlling restenosis becomes largely the problem of con. 
trolling the smaotb mu5clc cell re5pon5e to injury. Many 
approaches have been tried in an titempt tu achiive this. It 
is our belief, however, that succe55 will largely depend on 
acquiring a comprehensive knowkdgc ofche 11~4~~ular ml 
cellular mechanisms responsible far lbe smooul musek cell 
raspon* IO vascular iqiury and than developing a therapeu- 
tic slratcgy bastd w this knowledge. The purpose of this 
report, thcrcfore, is twofold: finr, (0 review the available 
information relevant to the5c mechanisms, and oecond, 10 
reviaw some of the new mokculnr-based slrategies cuwntly 
being explored as possible approaches to the control uf 
corunary rcslen&4 alter angioplssty. 
Muleednr and Cellular Meeban&msa 
Smooth muscle cells are nurmally quiescent (14). The 
angioplasty-induced iMury, however, denudes the vessel 
wall of endolhelial cells and traumatizes the media, effects 
tbat activate multi& siennl lransduction uathwavs lhpt 
ultimate!y result in nuclear events leading IO &noolhmuscle 
cell division and migralion. This end result is caused by two 
complementary effects of angioplasry: the removal of 
inhibitory inlluences and the induction of stimulatory ones 
(I?& I). 
Removal of lnbibiw lahnaa. Endothelial cells nor- 
mally secnte nitric oxide (15,141 and hepatan 5uIfaie pro- 
teoglycan (17). both of which inhibit smooth muscle cell 
proliferation. They also secrete prostacyclin IF’GIJ, which 
along with nitric oxide, inhibits platelet aggregation. Al- 
though it is likelv that the endothelial cells overlying an 
atheroma are dyslunctional and contribute little to antipro- 
Iiferative influences. to the extent they do. their removal by 
mechanical trauma of angiaplasly would further contribute 
IO the proliienuive environment. 
Wmetbn of sIim&tory ietlwmes. Platelets adhere to 
the injured vessel well. aggregate end release mitogenic 
growth faftors aud cytokines W-24). The plutelet response 
&o causes tbmmbus to develop et the site of injury. which 
further faeilitetes mulifemtive wocesses (24-28). In addi- 
tion, the thmmbin &weted dkng the pmce~s of thmmbus 
development (29) stimulates then pmliferation of smooth 
muscle c&s (30.31) end is n wtent uctivator of datelets 
(32,331 and chemoattractant fir monocytes (34). it is be- 
:ieved to induce the expression of cell adhesion molecules 
(35.36) end induces cndotheliel cells to express platelet- 
derived growth factor (37) and an inhibito: of plasminogen 
activator (38). Moreover, the underlying complex athero- 
sclerotic lesion contains macmphages and T ljgmphocyles 
(39) that when stimulated. exuress cvtokines and emwth 
&tors W-44). Not only &e s&mth &cle cells th;target 
of locally released milugenic factors, but in response to 
injury they them&w express smooth muscle cell genes 
encoding growth factors, cytokines and the receptors recog- 
nizing these ligands (45-65). 
Oxygen free radicats are also generated during vascul.x 
injury 166) and not only damage cell constituents. but also 
plsy a role in modulating the expression of many genes 
(67.68), the products of which add to the proliferative effects 
of vascular injury. As one example of such a pathway. tumor 
necrosis factor-alpha released by macropheges end smooth 
muscle cells stimulates production of oxygen free ndicela 
(69) and activates nuclear factor-kappa B (NF-KB) (701, a 
multifunctional transcription factor. 
The complexity of the response to injury is further 
increased by the Fact hat free radicals and various cytokines 
increase the expression of cell adhesion molecules, such as 
intercellular adhesion molecule-l (ICAM-I) and vascular cell 
adhesion molecule-l (VCAM-I) (71-73). Expressiunofthese 
and other related molecules leads to the recruitment of 
mono+zyte-derived mucrophages and neutrophils to tbe in- 
jured vessel. which add to the pools of cytokines, growth 
factors and free radicals already present, thereby further 
anhestnting and amplifying the response to injury. 
Hence, the environment of the vascular wall changes 
dramaticallv after iniurv. with the rea~ovai of inhibitory 
factors and the indu&n of proliferation factors. The “et 
effect of these changes is to stimulate smooth muscle cells to 
pmliferate and migrate, ultimately leading to the develop- 
ment of a usaintimal mass that in a substantial number of 
patients can compromise vascular Row. Some of the ceU 
types and the mitogenic products they release that are 
involved in the te~cawe to iniurv ere listed in Table I 
(74-88). 
T&k 1. Milogenr. Cytokims and Gmwth-Promoting Factors Synthesized by Various Cell Types 
Figure 2. Signal transduction pathway of the platelet-derived 
growth fmor (FDGFJ receptor. Binding ofplalelet4wivcd mwih 
factor (adid I&@HJ to its receptor C~UKS dinwimion of the 
receptor. This is followed by autapbospborylalion on a s&s of 
tyrosine residues present in the receptor’s inlracellular domain. 
Once phosphorylaicd. the phwletderived growth fanor receptor 
associates with mulliplc intracellular signaIling proteins, including 
phospholipase CJ-I (PLC), GTpase-activating protein (GAP) Md a 
subunit of phosphatidylinositol 3Dkinax (PI-3 kinm). leading to 
their phorphorylation and their activation of a variety of down- 
stream large&. GTP = guanosine triphusphatc; Ca = cakium: 
MAP = mitogen-aelivattd pm&in kinarcs; PI, ,P2 = phosphalidyl- 
inositol 4,5-biphosphate; IF, = inositol 1.4.5~kiphosphatc; DG - 
diasyl.glyceml; PKC = protein kinase C; PI,,P, = phosphatidytirra. 
silo1 3Mphosphate; @I = phosphorylated protein. 
Signal transduction pathways. The mechanism by which 
these many factors influence smooth muscle cells to prolif- 
erate and migrate is through the generation ofa signal that is 
initiated when the factor (ligand) binds with its specific 
cell-surface receptor. The information conveyed by ligand. 
receptor binding at the cell surface is transduced to the cell 
nucleus by a series of complex intracellular reactions, re- 
ferred to as a signal transduction pathway. A host of such 
receptor-ligand signal transduction pathways have been im- 
plicated in smooth muscle cell growth, and perhaps the best 
characterized is the interacrion of platelet.derived growth 
factor with its receptor (89-94) (Fig. 2). which stimulates 
smooth muscle ceil migration and proliferation (4.95-97). 
Complex pathways also exist for other smooth muscle 
cell mitogns, such as angiotensin II (5%100). endothelin 
(101,102) and the fibroblast growth factors (FGFs) (acidic 
and basic) (102-108). Binding of these mitogens to their 
receplors results in activation of a variety of intracellular 
signalling molecules and induction of a program of transcrip 
tional activalion similar to that produced by pIatekt-derived 
growth factor. The set of gene products induced whhin 
minutes to hours after exposure to growth factors are termed 
immediate early gene products (109). Although originally 
detected by studying cells in tissue culture, a host of 
immediate early genes are also activated after arterial i&ry 
in vivo (1 IO). 
Figure 3. Simplikd scheme of the cdl cycle and factors rerpMlsibk 
for cell prcWersioo. CDKs = cycliwbqxwknt protein kinaxs: 
EGF = epidcmul growib kctw; FGF = ~ibroblast gmwlb factor; 
IGPt = iasulin4ikc growlh factor-l; PLIGF = pktektderived 
growth factor; PCNA = pmtiferalinp cell nuck.a~ antigen; Rb and 
~53 = tumor suppressor genes. M = mitosis phase ufcett cycle; S = 
DNA synthesis pbasc: 0, and 0, = ccl1 growth phue: Go = 
quiescent phase: CD& = ceil division cyck 2. See text fur &tails. 
Tbs ceU cyde. The ullimaie consequence of activating 
these signaIling pathways is lo effect a series dintranuckar 
events that stimulate a cell to move from a quiescent to a 
proliferative state. Figure 3 depicts a simplified scheme of 
the cell cyck and some of the factors that stimulate qaks- 
cent cells (Gal to enter and progress through the cell cycle, 
during which they synlhesize proteins and enlarge (G,). 
replicate their DNA (S phase), continue to grow (GZ) and 
finally divide (M phase). 
Although much slill remains to be learned about the 
factors responsible for stimulating cells to enter and proceed 
through each of the specific cell cyck phases, considerable 
informalion is known (111-116). For example. phttelet- 
derived growlh factor cr fibroblast growth faetor are neces- 
sary for rendering cells competenr to enter the cell cycle; 
they are referred to as competence factors. Insulin-like 
growth factor-l and epidermal growth factor are necessary 
for cells tomove through the”nstriction poiat”(thepwint in 
0, that, when passed by the cell, commits the cell to 
complete the cell cycle): they are referred to as progression 
factors. Proliferating cell nuclear antigen (PCNA) has a 
multiittnc~iottal role in cell division that is ultimately neces- 
sary for DNA synthesis to occur (lt7,llS). The tumor 
suppressor genes Rb and ~53 encode proteins that inhibit 
cells from pmgrcssioo through Gt (119-123). For cells to 
proceed into S phase, the confonnutional state of these 
molecules conveying an inhibitory function must be altered 
(by dephosphorylating pS3 and phosphorylating Rb). thereby 
removing the G, block. 
One of the major controlling elements regulating pro- 
gression of cells through the cell cycle are an anay of 
complexes formed between seveti classes of cyclins and 
cyclindependent kinases (124.125) (Fig. 3). Thus. for pro- 
gression through G, to occur. cvclins D. E and A bind in a 
sequential m&e; to cyclin-dependent protein kinases 
(cdks), thereby activatingthe kinase (124-128). The complex 
formed between cyclin Band the cdd kinase. convenely. is 
critical for progression fmm the G, thmugh the M phases 
(129-132). As cells approach the G,IM boundary. cyclin B 
complexes with cdc2, and after a series of phosphorylations 
and dephosphorylations. the cdc2lcyclin complex advances 
the cell into the hi phase. Degradation of the cyclin portion 
of the complex allows the cell to proceed through the M 
phase. 
Treatment Strategies to hhibit Restenosis 
Many phammcdogic therapeutic interventions have been 
tested in experimental models of vascular injury and in 
clinical trials. An overview of the efficacy of these diverse 
therapeutic approaches has been the subject of several 
excellent reviews (8,133-135). In general. those approaches 
thal have been tested clinically either have failed despite 
reported success in various animal models of injury-Induced 
smooth muscle cell prolifersti~n or have not yet been tested 
adequately. Hence, it is not clear at this time whether any 
such attempts will be successful. Hawever. the increasing 
information with regard to injury-induced molecular events. 
described earlier. lends itself to the development of new 
molecular&ased strategies to inhibit smooth muscle cell 
pmliiemtion and thereby to reduce the likelihood of resten- 
osis. 
For example. blaking either the re!case or production of 
smooth muscle cell mitogens alter injury, the binding of 
pcptide mitogens to their receptors, the signal transduction 
pathways resulting from receptor nctivution, ihe expression 
of the immediate early genes or the factors needed for cell 
cycle progression all represent distinct targets for molecular 
intervention. What follows is a selective review of three 
experimental approaches with which we and many others 
have heen involved. each of which is derived from the 
insights gleaned from studying the biology of smooth muscle 
cell activation. 
Itemmbbwt cblmerk toxins. We were intrigued by an 
exprimental approach for the treatment of cancer, which 
we thought might also be applicable to the restenosis pro- 
cess. This appnxch involves the use of recombinant DNA 
technology (Fig. 4) to construct new cytotoxic agents tar. 
geted to cancer cells (136,137). 
One such class of targeted molecules is derived from 
Pseudomonas emtoxin, which is one of a class of adenosine 
RCceptor Recognized 
by Gene Product 
Cell Recognition 
Domain Deleted 
L”/“’ NO”e 
Figure 4. Use of recombinant DNA technology to conwuet chi- 
merit toxins targeted to specific ell surfx~ receptors. The wppw 
row depicts the naturally occurring gene encoding Pswdonmns 
m2min. an entremrly potent toxin: Domain I encodes the cell- 
binding domain: domain II cncodcs that portion of the molecule that 
tramlocates it into the cell cytosol: and domain 111 en&es the 
cell-killing domain. The intact P. m#o.~in gene product (righ. 
cebtm~ binds to the P. ~.wto.rin receptor and is cytouxic to 
virtually all cells. When its c&l-binding domain is either deleted or 
mutxted @and row). its cytotoxic effects are markedly reduced. 
When B gene encoding o ligand is fused 10 this mutaled toxin gene 
@h-d e!~d fourdz mm). the chimeric toxin expressed by the fusion 
gene specifically targets and kills only those cells that contain the 
cell surface xceptw rm?&ing the l&and. TGFo = transforming 
gcwth factor-alpha: other abbreviations as in Figure 3. 
diphosphate (ADP)_iibosyl transfemses that includes diph- 
theria toxin. Escherichia co/i enterotoxin and cholera toxin. 
After a single P. exoroxin molecule gains entry into the cell. 
it causes cell death by inactivating elongation factor 2. which 
stops protein synthesis. Its extremely potent toxic activity is 
mediated by its three domains: domain I is the cell-binding 
domda, domain II translocates the molecule into the cell 
cytosol, and domain III is the ceil-killing domain (138,139). 
Although the intact P. emtoxin molecule is cytotoxic to 
virtually nil cells, when its cell-binding domain is either 
deleted or mutated. its cytotoxic effects BP markedly re- 
duced: hence, when a gene encoding a ligand is fused to this 
mutated toxin gene. the chimeric toxin expressed by the 
fusion gene specifically targets only those cells that cuntain 
the cell surface receptor recognizing the ligand. These 
recombinant molecules gain eurty into the cell when the 
peptide ligand part of the recombinant molecule binds to its 
surface receptor and is subsequently internalized. Once the 
recombinant molecule is inside the cell. this molecular 
“Trojan horse” exerts its cytotunic effect through its bacte- 
rial toxin moiety. 
The specii%ity of such agents in targeting cancer cells 
resides in the observation that many taxer cells overex- 
press a variety of cell surface ,eceptors that facilitate the 
Flaw 5. khematic renresentatkn of the mechanism of sftion of 
&ewe oligonucleotidcs k&go). The process dprotdn expression 
invdves the tranxriotion of DNA to messmncr RNA fmRNA) and 
the trmdatkn cd r&N.4 Lo form rhe partis& twotein it e&der. 
Antisense oligonucleofides ore lakcn up by the cell aad hybridize (o 
their corrwponding mRNA Fomuaion of a dupiex nwtecuk. con- 
sisting of mRN.~~oligonuckoride. is dwugln 10 inhibif transklinn 
and lherefan protein synlhegia. See kr( for d&k. 
proliferative process. These overexpressed receptors can 
serve as the targels for recombinant fusion loxins. Of note, 
actively proliferating nonncoplastic cells also overexpress 
cerlain receptors. In particular, activated smooth muscle 
cells express higher numbers of cell surface receptor for 
platelelderived growth faclor. epidermal growth factor, 
fibroblast growthiactor and insulin.like growth factor-l than 
lheir nonactivated counlemarts 153.140-1471. 
Using several targel r&eplo;s. we found thal chimer& 
toxins can preferentially large( and kill rapidly proliierating. 
compared with quiescent. smooth muscle cells in vitro 
W6.148). Casscells et al (149) have shown similar effects 
using an agent produced by chemical conjugation of basic 
tibroblast growth factor 10 sapmin (a potent plam toxin). and 
other investigators tlSO.151) have reported that a fusion 
toxin consisting of an &red diphtheria toxin molecule 
ligated to the cytokine interleukin-2 or lo eoidenal growth 
f&or may interfere with smooth muscle &II prolife&ion. 
Preliminary in viva animal dam examining chimeric toxin 
approaches ID the inhibition of the smooth muscle cell 
response to vascular injury are pmmising (149-151). How- 
ever, more studies evaluating efficacy and toxicicy are 
needed because cells other than rapidly proliferating smooth 
muscle cells may have sufficient numbers of Ihe targeted 
receptors, so that nondesired cyloloxic elects occw. Alter- 
natively, destruction of the targeted smooth muscle cells 
may result in the release ofgrowth factors and cyrakines that 
might stimulate neighboring surviving smooth muscle cells 
to proliferate. thereby obviating or minimizing any beneficial 
effect. 
Antisaw strategies. IntraceUular taigeting to inhibii fx- 
tars necessary for cell proliferation and migration could be 
achieved by molecular-based approaches using antisense 
strategies. Such snategies provide a theoretically simple 
means to inhibit the exoression of a snecitic acne (152.1531. 
Messenger RNA &WA) contains seque ces’of m&- 
dides that encode for specific amino acids; hence, it con- 
veys a “~nse*’ message that results in the translation of a 
protein product. Antisense oliwmckotide strategies in- 
volve exposing cells to nlativ& shon DNA molecules 
~ontabd~~ 15 to m ~~~~tksized n~k0tide~ (an diaode~~- 
nuclwtid~) so that the nuckotiie seque&is c&pieme~- 
tary to the target mRN.4 and will therefoe hybridize with il. 
This oligodeoxynucleotide is referred to as an “antisense” 
molecuk: it not only fails to encode a message that can be 
translated into a protein, but once the antisense molecuk 
enters Abe cell and hybridizes with its complementary target 
mRNA, the mRNA canno+ be trvmslated, thus preventing 
expression of the protein product il encodes (Fii. 5). 
The precise mechanisms responsrMe for inhibiting gene 
expression in intact eukaryotk cells by anti~nse olii 
oxynucleotides are not known because most of mu eurmnt 
information is derived from studies perfamed either in 
c&free lranslation systems of in tIog mcytes. It is gmer- 
allv believed. BS deoicted in FL 5. tltat anantirense-sense 
duplex is formed in the cyto&sm and inhibits translatimt 
either by directly inhibiting ribosomal m oftbe codon 
or by tafgcling the mRNA for degmd&m by tibonuckase 
H. Altcmslively, ifanantisensedig&oxynuckotiientm~ 
the nucleus and hybridizes with its ccmpkmenCary mRNA. 
UK resulting dupkx weld interfere with spl* or could 
inhibit transpwt of Ihe mRNA from tbe nucleus into the 
cytoplasm (152.153). 
h pmviwsly discussed. cell prolifwationdepends on the 
expression of various immediie early gene products, 
gmwth factors and growth faclor receplws. and several 
studies on wansfonned cells and Mood cell liner have shown 
that targeting the messages of such factors witb antisense 
mokcuks reduces their expression. thereby inhibiting cell 
oroliferation U54-158). The em-iv enwicncc with lItis strat- 
&y lo inhibit smooth muxle &II ‘proliferation has been 
encouraging. Thus. antisense oligodeoxynuckotides target- 
inglbe mRNAoflbegene enccdingproliferalingcell nufkar 
amigen (Fig. 3) have been found IO inhibit. ir &o, smooth 
muscle cell omliferation tl59.1601. Similar results have been 
obtained 4th antis& oligo&oxynucleotides targeting 
r-myc or c-myb (nuclear ~ran.wiption factors). and thal 
targeling nonmuscle myosin (an essential component of 
cytokinesis, which leads to cell division) (M-163). We 
found that antisense oliiodeoxynucleotide targeted to the 
mRNA encodinn r-mvc also inhibited by 90% smooth musck 
cell migration (iG), L intrinsic comp&tt of Ihe re5tenosis 
pK?XXW.. 
‘The use of antisense techniques for the treatment of 
restenosis has gained considerable momentum with several 
successful in viva studies (16448) usingantisense oligcde- 
Fiwe 6. Gene transfer usins adenovims as a vector. Xeeombinant 
virus eat be mnstmcted that contains foreign. potentially therapu- 
tic genes. Tote recombinant adenovirus is made replication deficient 
for safely rea.wns. The resultant replication-d&ient recombinant 
vim can infect a wide range of cells but is incapable of replicatittg 
mtce inside P cell. Once gaining entry into the cell. the adenovirus 
laaliies to the nucleus. where the cell’s normal machinery is used 
to make high kvclr of the therapeutic gene product. 
oxymtcleotides lo c-myb. e-myc, proliicnting cell nuclear 
antigen plus cdc2 and pmliierating cell nuckar nntigcn 
alone. However, considerable technical problems must be 
ovct’come befon antisense technology cat be used clinically 
(169,9,17f0. Thus, high concentrations of antisense molecules 
arc often ttcccswy lo inhibit smooth muscle cell prolifeera- 
lion. possibly a rc&ction of low cellular oligodeoxyttucle- 
otide uptake or rapid degradation of oligodeoxynucieotidcs 
within the ce!l. Oliicaxynucleotides have been modified 
to avoid the problem of their rapid degradation. These 
modiiatioas, however. can increase nonspecific toxic ef- 
fects or reduce potency. Moreover. it is now clear that 
antiscast oligodeoxynttcleotidcs arc not as swcific as was 
oocc thought bea& they can bind not onl; to the target 
mRNA with which thev arc fullv comolcmentarv but also to 
other mRNAs with which the; sh& only pa&l complr 
mcnIarity. Most disturbing, they can bind ID various pro- 
teins, and, in the process. alter the functional characteristics 
of the protein. 
&me tbcrapy. The past S years have seen rcm..:kabk 
progress itt attempts to lrcnt poetic or acquired diseases by 
altetittgpnecxprcssion. lnenpetimcnts nttcmptingto trans- 
fer fonigo genes into the vascular wall, investigators have 
focused on two methods of gene delivery: liposame- and 
virukmcdiatcd gene trattsfcr (171-178). Liposomcs arc lipid 
vesicles (ha1 envelope DNA fragments. By fusing with the 
cell mcmbratx, tbcy facilitate entry of DNA into cells. Viral 
vectors arc constructed so that the foreign gene to be 
tmttsfcrrcd is integrated within the vital gcnome. The gene is 
delivered to tbc target cell through tbc process of viral 
ink&n (Fig. 6). With either method. DNA taken up by 
cells is then traosctibed and translated to produce the 
therapeutic protein. 
Any strategy to treat rcstcnosis by UEI of gene therapy 
techniques will require a high efficiettcy of gene transfer into 
cells of the vascular wall. All previous attemots that relied 
on liposomal or retrovir&based systems to tt&fcct vascu- 
lar cells in viva sut%rcd fmm a low overall ttansfection 
efficiency. Estimatesofgenctransferwerefmm <I in lO.wO 
cells to -I in l,ooO cells (172). Such a low ctficiency of gene 
transfer is unlikely to be sufficient to provide a therapeutic 
benefit. However. recent studies suggest that lipcsome- 
based methods might bc improved by optimizing either the 
promoter elements or the DNAniposome ratio (179). 
One approach that attempts to circumven: the in vivo 
problem of low trmtsfection efficiency is seeding the vascttlx 
wall with ~cnetically modified cells. In this aooroach. cells . . 
grown in culture arc trattsfccted using rctrovinl vectors. 
They are then reimplamed into the arterial wall in the hope 
that they will attach and express the gate of interest. tnitial 
attempts have suggested that ettdothelial cells infected in 
vitro and reintroduced into M injured artery adhere to the 
arterial surfttcc attd cotttinually express foreign gcnc prod- 
ucts (174.175). Similar strategies have been used with gcnct- 
ically modit?ed smooth muscle cells that also appear to 
adhere to injured or~eries and express their for&t gene 
oroducts for >6 months 1176.177). In addition to the treat- 
ment of rcstenosis, this approach of using in vitro infection 
followed by in viva implantation may be useful in modifying 
intravascular stents or bypass grafts with gcttcticdly altered 
cells (17S.L78.180). 
Finally. newer vectors. such as recombinant rcplication- 
deficient adettovirus vectors, hold great promise (181.182). 
Unlike rewviws vectors. which arc able to tt-ansfxt and 
express their gene produ:ts successfully only in actively 
twolkntine cells (183). adenovirus vectors can transfer and 
&press cx&cnou~ DNA in a wide varicIy of replicating and 
nonreplicating mammalian cells (181-183). Reports from 
several laboratories indicate that recombinant adenovirus 
vectors etlkienlly transfer genes into vascular endothelial 
cells both in vitro and in viva KM-186). We and others 
(187.188) have tested a repliea~on-d&iettt recombinant 
adenoviros that contains the marker gene beta-galactosidasc 
in vascular smooth muscle cells. This vector is highly 
efficient in infecting and expressing its gene product in rat 
aortic smooth muscle cells grow in c~lt~rc (187,188). It was 
also found that uninjured nt carotid artcries showed tieno- 
virus-mediated gc~c transfer limited to the endathelium, 
whereas ballo&njured arteries exposed to adenovintr a 
various time points after injury showed high efficiency of 
beta-galactosidase expression in cells not covered by an 
intact internal elastic membmtte. Thus, neointimal smooth 
muscle cells showed high levels of beta-salactosidase ex- 
pression. whereas toed% smwth mu& cells that arc 
covered by the internal elastic membrane could only be 
infected after considerable. injury, which presumably com- 
promises its integrity (187,188). 
With the highly efficient ability to transfer genes into 
arterial smooth muscle cells. it should now he possible to 
select nume~x cellular targct~ for gene therapy. Among 
these are growth factors and cytokines and their receptors, 
components of sigotd transduction pathways necessary for 
cell proliferation, transcription factors and proteins oeces- 
sary for cells to progress through the cell cycle (Fig. I to 3). 
Inhibition of these factors may be made possible by deliver- 
inggenesexpressingeitherantisense transcriptsardominant 
negative gene products. Smooth muscle cells could also be 
transfected with genes whose products act as vasodilators, 
antiplatelet or antithrombotic agents or inhibitors of prolif- 
eration. Included among such genes are nitric oxide syn- 
thase, tissue-type plasminogen activator, hirudin. pros- 
taglandin H synthasc and the tumor suppression gene ~53. 
Because free radicals are expressed during injury and are 
believed to p!ay an important role in the activation of 
numerous genes (66-60, a strategy to deliver genes to 
smooth muscle cells encoding such free radical scavenger 
enzymes as superoxide dismutare or cat&e could also be 
tested. 
A somewhat dilierent strategy would be to express the 
gene encoding herpes simplex thymidine kinax. When this 
gene is expressed in mammalian cells, cell proliieration can 
be inhibited by exwwre of the cells to the drug wciclovir, 
B nucleoside~anaiogue (189). Herpes simpl&- thymidine 
kinase preferentially phosphorylates ganciclovir to form a 
nucleotide analogue that, after being incorporated into the 
elongating DNA strand. inhibits further DNA synthesis. 
Thus, delivery of this gene to smooth muscle cells, with 
subsequent exposure to ganciclovir, represents yet another 
approach to control of smwth mwcle cell proliferation and 
therefore the treatment of restenosis. 
Gmclusions. The major advances being made in under- 
standing the cellular and molecular mechanisms responsible 
for cell proliferation in general and for the smooth muscle 
cell response to vascular injury in particular have helped lay 
the groundwork for cow therapeutic approaches to the 
Problem ofrestenosis after aneiodastv. We have touched on 
ogy and targeted gene therapy. These, and undoubtedly 
other modalities, may be tested in human clinical trials in the 
not too distant future. Only then can their elficacy and safety 
be truly evaluated. History would suggest that some will be 
Gective for tnatine. restenosis but ocrhaw not without . 
some untoward side effecrs. 
Somewhere, Robert Bums is smiling. 
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